Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Mycosis fungoides (MF) is associated with increased risk of second primary hematologic malignancies, but its association with second primary solid tumors is less well characterized.
This retrospective analysis seeks to assess the risk of being diagnosed with a second primary hematologic or solid malignancy in patients with MF.
We performed an analysis of patients diagnosed with MF from 2000 through 2015 in the United States cancer registries of SEER-18 (N = 6742).
Relative risks were estimated by using standardized incidence ratios (SIRs). Among 6742 patients, there were 511 (7.5%) second cancer events (SIR, 10.15; 95% confidence interval [CI], 9.29-11.07). These included 184 (36.0%) hematologic malignancies (SIR, 39.71; 95% CI, 34.05-46.05) and 327 (64.0%) solid tumor malignancies (SIR, 7.33; 95% CI, 6.56-8.17). Patients with MF were at increased risk for non-Hodgkin lymphoma; Hodgkin lymphoma; melanoma; and lung, female breast, prostate, colon, and renal cancers. Females were at higher risk than males (P < .05). All ethnic groups showed a statistically significant elevation in SIRs. Elevation of SIRs was observed across all stages of MF.
Conclusions and Relevance
Patients with MF are at increased risk for diagnosis of second primary malignancies and should be carefully screened for discernable signs and symptoms of second malignancies.Le texte complet de cet article est disponible en PDF.
Key words : CTCL, cutaneous lymphoma, cutaneous T-cell lymphoma, mycosis fungoides, non-Hodgkin lymphoma, second malignancy, SEER, Surveillance Epidemiology and End Results
Abbreviations used : CI, HR, MF, SEER, SIR
| Funding sources: Supported by an HONORS (Hematology Opportunities for the Next Generation of Research Scientists) award research grant from the American Society of Hematology. Statistical analysis was in part supported by National Institutes of Health grant P30 CA77598 usign the Biostatistics and Bioinformatics Core shared resource of the Masonic Cancer Center, University of Minnesota and by the National Center for Advancing Translational Sciences of the National Institutes of Health award number UL1TR000114. This funded the statistical analysis. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
| Conflicts of interest: None disclosed.
| Reprints not available from the authors.